This clinical trial is focused on patients with various types of cancer who are currently benefiting from treatment with the medications dabrafenib and/or trametinib. These medications are used to treat certain types of cancer by targeting specific proteins in cancer cells, which can help slow down or stop the growth of the cancer. The study aims to provide continued access to these treatments for patients who have been part of previous studies sponsored by Novartis or GSK and are still experiencing benefits from the treatment.

The purpose of the study is to assess the long-term safety of these medications. Participants will continue to receive their current treatment, either as a single medication or in combination, depending on what they were receiving in the previous study. The study will monitor the occurrence of any side effects or adverse events to ensure the ongoing safety of the treatment. Patients will have regular check-ups with their healthcare providers to evaluate their health and the effectiveness of the treatment.

This study is designed for patients who have already been receiving dabrafenib and/or trametinib and have shown compliance with the treatment plan. The study will continue until the end of 2027, allowing patients to maintain their treatment regimen under the supervision of their healthcare team. The goal is to ensure that patients who are benefiting from these medications can continue to do so safely over a longer period.